Literature DB >> 11788901

Frequent allelic losses on the short arm of chromosome 1 and decreased expression of the p73 gene at 1p36.3 in squamous cell carcinoma of the oral cavity.

Daisuke Araki1, Katsuhiro Uzawa, Toshihide Watanabe, Masashi Shiiba, Akihisa Miyakawa, Hidetaka Yokoe, Hideki Tanzawa.   

Abstract

Frequent loss of heterozygosity (LOH) on the short arm of chromosome 1 (1p) has been reported in a series of human malignancies. To investigate the possible existence of tumor suppressor locus (or loci), we examined 41 primary oral squamous cell carcinomas (OSCCs) for LOH using a panel of 15 polymorphic microsatellite markers located on 1p. LOH was observed in 30 of 41 cases (73%) that were informative for at least one of the loci analyzed. Two distinct regions of common allelic loss were identified: a distal region at D1S243 (1p36.3), and proximal region at D1S160 (1p36.1). In addition, the possible involvement of the p73, a candidate tumor suppressor gene located on 1p36.3, was also evaluated. Polymerase chain reaction-single strand conformation polymorphism (PCR-SSCP) analysis revealed no mutation of the gene in all samples analyzed (n=41). On the other hand, semi-quantitative reverse transcription-PCR (RT-PCR) demonstrated that 25% of primary tumors (n=20) had absent or reduced mRNA expression of the p73 gene. All cases showing down-regulation of the p73 gene were clinically classified as stage IV, but we could not detect any LOH at the gene locus in the same samples. Furthermore, re-expression of the p73 gene mRNA was induced in OSCC-derived cell lines showing down-regulation of the gene expression after treatment with 5-aza-2'-deoxycytidine, a DNA demethylating agent. These findings suggest that there may be at least two distinct tumor suppressor genes inactivated by allelic deletion on 1p31.1 and 1p31.3, respectively. In addition, the p73 gene could be inactivated by the methylation-dependent silencing of this gene, and associated with the tumor progression of human OSCC.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11788901

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  7 in total

Review 1.  Can colorectal cancer be prevented or treated by oral hormone replacement therapy?

Authors:  P Li; J E Lin; S Schulz; G M Pitari; S A Waldman
Journal:  Curr Mol Pharmacol       Date:  2009-11       Impact factor: 3.339

Review 2.  Chromosomal aberrations related to metastasis of human solid tumors.

Authors:  Lun-Xiu Qin
Journal:  World J Gastroenterol       Date:  2002-10       Impact factor: 5.742

3.  Evaluation of 1p36 markers and clinical outcome in a skull base chordoma study.

Authors:  Mauro Longoni; Francesca Orzan; Michela Stroppi; Nicola Boari; Pietro Mortini; Paola Riva
Journal:  Neuro Oncol       Date:  2007-12-19       Impact factor: 12.300

4.  1alpha,25-Dihydroxyvitamin D3 potentiates cisplatin antitumor activity by p73 induction in a squamous cell carcinoma model.

Authors:  Yingyu Ma; Wei-Dong Yu; Pamela A Hershberger; Geraldine Flynn; Rui-Xian Kong; Donald L Trump; Candace S Johnson
Journal:  Mol Cancer Ther       Date:  2008-09       Impact factor: 6.261

5.  E2F2 suppresses Myc-induced proliferation and tumorigenesis.

Authors:  Raju V Pusapati; Regina L Weaks; Robert J Rounbehler; Mark J McArthur; David G Johnson
Journal:  Mol Carcinog       Date:  2010-02       Impact factor: 4.784

6.  Gene expression in uninvolved oral mucosa of OSCC patients facilitates identification of markers predictive of OSCC outcomes.

Authors:  Pawadee Lohavanichbutr; John Houck; David R Doody; Pei Wang; Eduardo Mendez; Neal Futran; Melissa P Upton; F Christopher Holsinger; Stephen M Schwartz; Chu Chen
Journal:  PLoS One       Date:  2012-09-28       Impact factor: 3.240

7.  WWP2-WWP1 ubiquitin ligase complex coordinated by PPM1G maintains the balance between cellular p73 and ΔNp73 levels.

Authors:  Neelam Chaudhary; Subbareddy Maddika
Journal:  Mol Cell Biol       Date:  2014-07-28       Impact factor: 4.272

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.